17367
document
An open and randomized study comparing the efficacy of standard danazol and modified triptorelin regimens for postoperative disease management of moderate to severe endometriosis . OBJECTIVE To compare the efficacy of danazol and triptorelin ( Decapeptyl CR , Ferring , Kiel , Germany ) in the management of moderate and severe endometriosis in terms of symptom control and revised American Fertility Society ( AFS ) score reduction , and to evaluate the hormonal profile of patients treated with triptorelin every 6 weeks . DESIGN Open and randomized trial . SETTING Kwong Wah Hospital , a large public hospital in an urban location ( Hong Kong ) . PATIENT ( S ) Forty patients after their first conservative operation for endometriosis , with surgical confirmation of revised AFS stage III or IV endometriosis . INTERVENTION ( S ) Postoperative 6 months ' therapy of danazol or triptorelin every 6 weeks , postmedical therapy second-look laparoscopy . MAIN OUTCOME MEASURE ( S ) Symptom control and patients ' tolerance during medical therapy , posttherapy revised AFS score , hormonal profile during triptorelin therapy . RESULT ( S ) Pain control was similar between danazol and triptorelin therapy . There was less breakthrough bleeding with triptorelin . More patients failed to complete the whole course of danazol because of its side effects . The revised AFS score at second-look laparoscopy did not show a significant difference between the two medications . Adequate pituitary suppression was observed with injection of triptorelin every 6 weeks . CONCLUSION ( S ) Lengthening of triptorelin administration intervals from 4 weeks to 6 weeks is effective in maintaining a hypoestrogenic state . Patients were more compliant with triptorelin than danazol . Thus , triptorelin injection every 6 weeks is more cost-effective than conventional regimens .
17368
Intervention_Pharmacological
standard danazol
17369
Intervention_Pharmacological
modified triptorelin regimens
17370
Intervention_Pharmacological
danazol
17371
Intervention_Pharmacological
triptorelin
17372
Intervention_Pharmacological
triptorelin
17373
Intervention_Pharmacological
danazol
17374
Intervention_Pharmacological
triptorelin
17375
Intervention_Pharmacological
danazol
17376
Intervention_Pharmacological
triptorelin
17377
Intervention_Pharmacological
triptorelin
17378
Intervention_Pharmacological
danazol
17379
Intervention_Pharmacological
triptorelin
17380
Intervention_Pharmacological
triptorelin
17381
Intervention_Pharmacological
triptorelin
17382
Intervention_Pharmacological
danazol
17383
Intervention_Pharmacological
triptorelin
17384
Outcome_Other
efficacy
17385
Outcome_Other
efficacy
17386
Outcome_Physical
symptom control
17387
Outcome_Physical
American Fertility Society ( AFS ) score reduction
17388
Outcome_Physical
hormonal profile
17389
Outcome_Physical
Symptom control and patients ' tolerance
17390
Outcome_Physical
posttherapy revised AFS score
17391
Outcome_Physical
hormonal profile during triptorelin therapy
17392
Outcome_Pain
Pain control
17393
Outcome_Physical
breakthrough bleeding
17394
Outcome_Adverse-effects
side effects .
17395
Outcome_Physical
revised AFS score
17396
Outcome_Physical
Adequate pituitary suppression
17397
Outcome_Physical
hypoestrogenic state .
17398
Outcome_Mental
compliant
17399
Participant_Condition
moderate to severe endometriosis
17400
Participant_Sample-size
Forty
17401
Participant_Condition
AFS stage III or IV endometriosis